earnings
confidence high
sentiment positive
materiality 0.85
Zimmer Biomet Q4 sales $2.02B (+4.9% CC), adj. EPS $2.31; guides FY2025 adj. EPS $8.15-$8.35
ZIMMER BIOMET HOLDINGS, INC.
2024-FY EPS reported
$4.43
revenue$7,678,600,000
- Q4 net sales $2.023B (+4.9% constant currency); Q4 adjusted diluted EPS $2.31.
- Full-year net sales $7.679B (+4.8% CC); full-year adjusted diluted EPS $8.00.
- FY2025 guidance: constant currency revenue growth 3%-5%; adjusted diluted EPS $8.15-$8.35.
- Announced definitive agreement to acquire Paragon 28 (FNA) for foot & ankle segment; terms not disclosed.
- Received FDA PMA for Oxford Cementless Partial Knee and FDA 510(k) for OsseoFit Stemless Shoulder.